Cargando…
The gut mycobiome: The overlooked constituent of clinical outcomes and treatment complications in patients with cancer and other immunosuppressive conditions
Autores principales: | Galloway-Peña, Jessica R., Kontoyiannis, Dimitrios P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7117661/ https://www.ncbi.nlm.nih.gov/pubmed/32240277 http://dx.doi.org/10.1371/journal.ppat.1008353 |
Ejemplares similares
-
Decades-old studies of fungi associated with mammalian lungs and modern DNA sequencing approaches help define the nature of the lung mycobiome
por: Hamm, Paris S., et al.
Publicado: (2020) -
Observational Cohort Study of Oral Mycobiome and Interkingdom Interactions over the Course of Induction Therapy for Leukemia
por: Robinson, Sarah, et al.
Publicado: (2020) -
Natural product ligands of FKBP12: Immunosuppressive antifungal agents FK506, rapamycin, and beyond
por: Rivera, Angela, et al.
Publicado: (2023) -
Drosophila as a model for the gut microbiome
por: Ludington, William B., et al.
Publicado: (2020) -
B vitamin acquisition by gut commensal bacteria
por: Putnam, Emily E., et al.
Publicado: (2020)